
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc. has demonstrated a solid performance amidst challenging market dynamics, positioning itself favorably as the reimbursement landscape evolves within the advanced wound care sector. The company benefits from an extensive portfolio of regenerative medicine products, with significant growth potential indicated by a projected operating profit increase and a final rate adjustment for reimbursement slated for CY2026. With shares currently trading at a discount compared to peers and an under-penetrated market opportunity, the outlook for further gains and market share expansion remains strong for Organogenesis Holdings.
Bears say
Organogenesis Holdings Inc. is facing significant challenges that warrant a negative outlook, particularly concerning its revenue growth and operational expenses. The company has been burdened by rising research and development costs without anticipated improvements in financial performance, leading to concerns over the growth of its key product PuraPly and the impact of Medicare Part B pricing on amniotic products. Additionally, the potential for competitive pressures and regulatory hurdles may hinder the company's ability to capture market share, compounded by expectations of reduced sales force effectiveness and higher operational costs associated with ongoing programs, such as the ReNu initiative.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares